Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments
This NOFO supports integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States.
Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C.
Applicants should develop a jurisdictional viral hepatitis elimination plan, promote comprehensive hepatitis B and C reporting, improve HBV and HCV testing policies, and increase healthcare providers trained to treat hepatitis B and C.
Contingent on funding, the following activities can be supported:
surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics); and increased access to services preventing viral hepatitis and other bloodborne infections among persons who inject drugs (PWID).
Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of hepatitis B, C and HIV among PWID in jurisdictions disproportionately affected by high-risk drug use.
Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.
Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A, B and C, and chronic hepatitis C.
Applicants should develop a jurisdictional viral hepatitis elimination plan, promote comprehensive hepatitis B and C reporting, improve HBV and HCV testing policies, and increase healthcare providers trained to treat hepatitis B and C.
Contingent on funding, the following activities can be supported:
surveillance for chronic hepatitis B and perinatal hepatitis C; increased hepatitis B and C testing and referral to care in high-impact settings (syringe services programs (SSPs), substance use disorder treatment centers, correctional facilities, emergency departments and sexually transmitted disease clinics); and increased access to services preventing viral hepatitis and other bloodborne infections among persons who inject drugs (PWID).
Contingent on funding, an optional component will support improved access to prevention, diagnosis, and treatment of hepatitis B, C and HIV among PWID in jurisdictions disproportionately affected by high-risk drug use.
Expected outcomes include improved surveillance for viral hepatitis, increased stakeholder engagement in viral hepatitis elimination planning, and improved access to viral hepatitis prevention, diagnosis, and treatment among populations most at risk.
Agency: Department of Health and Human Services
Office: Centers for Disease Control - NCHHSTP
Estimated Funding: $341,020,000
Office: Centers for Disease Control - NCHHSTP
Estimated Funding: $341,020,000
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/pa-files/PAR-20-059.html
Additional Information of Eligibility:
State governments or their bona fide agents (includes the District of Columbia)Local governments or their bona fide agents
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/pa-files/PAR-20-059.html
Contact:
Agency Email Description:
Grants Policy
Agency Email:
Date Posted:
2020-03-11
Application Due Date:
Archive Date:
2020-06-10
Social Entrepreneurship
Spotlight
Rwanda as Social Entrepreneur Fund Beneficiary
The Republic of Rwanda has been picked as one of the six African countries as beneficiaries for a new fellowship fund program designed at supporting social entrepreneurs in tackling issues on food security.
Learn How to Identify and Avoid Grant Scams
